Who Paid My Doc
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
ClinicalTrials.gov NCT05264129
Research payments
$4,660,085
Through program year 2024, $4,660,085 in research payments was reported against Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine, across 660 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT05264129
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $30,150 | 8 |
| 2023 | Research | $1,724,232 | 310 |
| 2022 | Research | $2,905,703 | 342 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Maryann Colvard Portland, OR Named on 64 payments
- Eva-Maria Heurich Orlando, FL Named on 33 payments
- Joseph Mann Rochester, NY Named on 24 payments
- Sridhar Guduri Dublin, OH Named on 22 payments
- Hayes Williams Vestavia, AL Named on 18 payments
- Ashok Patel Toms River, NJ Named on 17 payments
- Sherry Soefje Oceanside, CA Named on 16 payments
- Jon Finley Stockbridge, GA Named on 15 payments
- Helen Stacey Walnut Creek, CA Named on 15 payments
- Robert Strzinek Hurst, TX Named on 15 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.